Galectin Therapeutics Inc (NASDAQ:GALT) will release its earnings data before the market opens on Monday, August 14th. Analysts expect Galectin Therapeutics to post earnings of ($0.13) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Monday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. On average, analysts expect Galectin Therapeutics to post $-0.5 EPS for the current fiscal year and $-0.56 EPS for the next fiscal year.

Shares of Galectin Therapeutics Inc (NASDAQ GALT) opened at 2.11 on Monday. Galectin Therapeutics Inc has a 52 week low of $0.49 and a 52 week high of $3.68. The company’s market cap is $73.15 million. The stock’s 50 day moving average price is $2.33 and its 200-day moving average price is $2.18.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at

Several research analysts recently issued reports on the company. Zacks Investment Research raised Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Tuesday, May 30th. ValuEngine cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Galectin Therapeutics currently has a consensus rating of “Hold” and an average price target of $2.25.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Earnings History for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Stock Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related stocks with our FREE daily email newsletter.